

Bridion - (200 mg/2 mL and 500 mg/5 mL; Solution, Intravenous)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Sugammadex Sodium | Innovator | Merck |
| Dosage | 200 mg/2 mL and 500 mg/5 mL; Solution, Intravenous | Branded US Sales | More Than \$1000 mn |
| Probable FTF | More Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | More Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.